These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 26259912)

  • 21. Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab.
    Schoettler M; Duncan C; Lehmann L
    Pediatr Transplant; 2019 May; 23(3):e13381. PubMed ID: 30828947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombotic Microangiopathy After Hematopoietic Stem Cell and Solid Organ Transplantation: A Review for Intensive Care Physicians.
    Nusrat S; Davis H; MacDougall K; George JN; Nakamura R; Borogovac A
    J Intensive Care Med; 2024 May; 39(5):406-419. PubMed ID: 37990516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy.
    Bohl SR; Kuchenbauer F; von Harsdorf S; Kloevekorn N; Schönsteiner SS; Rouhi A; Schwarzwälder P; Döhner H; Bunjes D; Bommer M
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2172-2177. PubMed ID: 28860002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options.
    Kim SS; Patel M; Yum K; Keyzner A
    Transfusion; 2015 Feb; 55(2):452-8. PubMed ID: 25209960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
    Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
    Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
    N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical characteristics of pediatric allogeneic hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA): a retrospective single-center analysis.
    Luo L; Xiong H; Chen Z; Yang L; Sun M; Lu W; Tao F; Wang Z; Li J; Li Z; Tang S
    Clin Transl Oncol; 2023 Aug; 25(8):2451-2461. PubMed ID: 36973479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.
    Elsallabi O; Bhatt VR; Dhakal P; Foster KW; Tendulkar KK
    Clin Appl Thromb Hemost; 2016 Jan; 22(1):12-20. PubMed ID: 26239316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?
    Dhakal P; Bhatt VR
    Bone Marrow Transplant; 2017 Mar; 52(3):352-356. PubMed ID: 27775697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.
    García-Martín P; Alarcón-Payer C; López-Fernández E; Moratalla L; Romero A; Sainz J; Ríos R; Jurado M
    Ann Pharmacother; 2015 Sep; 49(9):986-94. PubMed ID: 26160968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report.
    Safa K; Logan MS; Batal I; Gabardi S; Rennke HG; Abdi R
    Clin Nephrol; 2015 Feb; 83(2):125-9. PubMed ID: 24495904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study.
    Svec P; Elfeky R; Galimard JE; Higham CS; Dalissier A; Quigg TC; Bueno Sanchez D; Han Lum S; Faraci M; Cole T; Pichler H; Benítez-Carabante MI; Horakova J; Gonzalez-Vicent M; Yanir A; Fagioli F; Wölfl M; von der Weid N; Protheroe R; Krivan G; Speckmann C; James B; Avcin SL; Bertrand Y; Verna M; Riha P; Patrick K; Cesaro S; Kalwak K; Bierings M; Büchner J; Mellgren K; Prohászka Z; Neven B; Lankester A; Corbacioglu S
    Bone Marrow Transplant; 2023 Feb; 58(2):129-141. PubMed ID: 36333550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical analysis of 9 patients with transplant-related thrombotic microangiopathy].
    Zhang BL; Zhou J; Gui RR; Zu YL; Zhang YL; Song YP
    Zhonghua Nei Ke Za Zhi; 2019 Jun; 58(6):423-427. PubMed ID: 31159520
    [No Abstract]   [Full Text] [Related]  

  • 34. A Heterozygous CFHR3-CFHR1 Gene Deletion in a Pediatric Patient With Transplant-associated Thrombotic Microangiopathy Who was Treated With Eculizumab.
    Nozawa A; Ozeki M; Hori T; Kawamoto N; Hirayama M; Azuma E; Fukao T
    J Pediatr Hematol Oncol; 2018 Nov; 40(8):e544-e546. PubMed ID: 28991129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature.
    Java A; Edwards A; Rossi A; Pandey R; Gaut J; Delos Santos R; Miller B; Klein C; Brennan D
    Transpl Int; 2015 Sep; 28(9):1121-5. PubMed ID: 25864519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy.
    Epperla N; Li A; Logan B; Fretham C; Chhabra S; Aljurf M; Chee L; Copelan E; Freytes CO; Hematti P; Lazarus HM; Litzow M; Nishihori T; Olsson RF; Prestidge T; Saber W; Wirk B; Yared JA; Loren A; Pasquini M
    Br J Haematol; 2020 Jun; 189(6):1171-1181. PubMed ID: 32124435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
    Genere L; Bacchetta J; Bertrand Y; Javouhey E; Cheikh N; Sellier-Leclerc AL
    Arch Pediatr; 2018 Nov; 25(8):485-488. PubMed ID: 30340942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.
    de Holanda MI; Pôrto LC; Wagner T; Christiani LF; Palma LMP
    Clin Rheumatol; 2017 Dec; 36(12):2859-2867. PubMed ID: 28905254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation.
    Gavriilaki E; Sakellari I; Batsis I; Mallouri D; Bousiou Z; Vardi A; Yannaki E; Constantinou V; Tsompanakou A; Vadikoliou C; Kaloyannidis P; Bamihas G; Anagnostopoulos A
    Clin Transplant; 2018 Sep; 32(9):e13371. PubMed ID: 30080283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival.
    Caires RA; Marques ID; Repizo LP; Sato VA; Carmo LP; Machado DJ; de Paula FJ; Nahas WC; David-Neto E
    Transplant Proc; 2012 Oct; 44(8):2388-90. PubMed ID: 23026601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.